

For Further Information Contact:

Roy Wolvin
Nymox Pharmaceutical Corporation
1-800-93NYMOX
www.nymox.com

For Immediate Release:

**Nymox Saliva Test Strongly Supported By New Independent Study
Data Published in *Cancer Epidemiology Biomarkers & Prevention***

HASBROUCK HEIGHTS, NJ (September 18, 2007) Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce the new publication of an independent study reporting positive data on the accuracy and usefulness of the Company's Saliva NicAlert™ test for tobacco exposure in a family practice setting. Saliva NicAlert™ results using saliva samples tested on-site closely matched those obtained by much more expensive and complex testing technology using urine samples sent off-site to an independent reference laboratory. Importantly, Saliva NicAlert™ was able to correctly identify smokers who reported being nonsmokers but were ascertained to actually be smokers based on the reference laboratory liquid chromatography/mass spectroscopy results.

The paper, "Validation of Self-Reported Smoking Status Using Saliva Cotinine: A Rapid Semiquantitative Dipstick Method," (*Cancer Epidemiol Biomarkers Prev.* Sep 2007;16:1858-62) is in the current issue of *Cancer Epidemiology Biomarkers & Prevention*, published by the American Association for Cancer Research (AACR) and is co-authored by principal investigators, Dr. Norman J. Montalto and Dr. Wayne O. Wells, both physicians with long-standing interest and expertise in the field of tobacco use and dependency. The studies involved 172 patients aged 6 to 80 at family practice medical clinics supervised by Dr. Montalto and Dr. Wells

"It is widely believed that physicians should routinely verify the smoking status of every patient. There are many situations where an accurate and convenient on the spot test is particularly important, such as preoperative assessment, allergy and pregnancy clinics or when prescribing oral contraceptives. Saliva is easy to obtain and having immediate results gives the clinician a powerful tool to counsel patients", said Brian Doyle, Senior Manager for Saliva NicAlert™.

NicAlert™ Saliva, the Company's saliva-based version of its NicAlert™ product, has achieved certification with the CE Mark, permitting its sale in the European Union. The new product uses easily obtainable saliva samples to provide an easy-to-use, on-site visual read-out of an individual's level of tobacco use or exposure. The product requires no instruments or special training. The urine-based version of NicAlert™ received clearance from the U.S. Food and Drug Administration and achieved certification with the CE Mark.

Cigarette smoking is the single most preventable cause of premature death in the United States. Each year, over 400,000 people die as a result of tobacco use and exposure in the U.S. alone. Experts in the field have long advocated that physicians should treat the routine assessment of smoking and other tobacco product use of patients in the clinic as an important "vital sign" for health risk reduction strategies and appropriate disease management.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The conduct of clinical trials and the development of drug and diagnostic products involve substantial risks and uncertainties and actual results may differ materially from expectations. Promising early results do not ensure that later stage or larger scale clinical trials will be successful or will proceed as expected. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.